ImmusanT
ImmusanT is a Cambridge, Massachusetts-based clinical-stage biotechnology company founded in 2011 that develops diagnostics and therapeutics for celiac disease, funded by Vatera Healthcare Partners, ARCH Venture Partners, and the JDRF T1D Fund.
- Company typePrivate
- Founded2011
- HeadquartersCambridge, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What ImmusanT does
ImmusanT is a privately held clinical-stage biotechnology company founded in 2011 and headquartered in Cambridge, Massachusetts. The company is focused on developing diagnostics and therapeutics for celiac disease, an autoimmune disorder triggered by gluten ingestion. Its work is centered on immunotherapeutic approaches and diagnostic tools designed to address the underlying immune response rather than symptom management alone. The short description in the firmographics explicitly identifies ImmusanT as a biotechnology company developing diagnostics and therapeutics for the diagnosis and treatment of celiac disease, indicating a single-indication focus and a translational R&D profile rather than a platform business.
The company has raised approximately $72.78 million in private financing across three priced equity rounds between 2011 and 2017, with lead backing from Vatera Healthcare Partners and ARCH Venture Partners; a subsequent 2018 investment from the JDRF T1D Fund points to potential adjacency into type 1 diabetes and related autoimmune indications. Leadership combines the Chief Scientific Officer and Chief Medical Officer roles in a single executive (Bob Anderson), with Maury Matteodo serving as CFO. The organization is small, with 11-50 employees, consistent with a lean clinical-stage operating model. The commercial website currently displays only a verification/loading page, suggesting limited active digital infrastructure or public-facing communications at the time of data capture.
The business model is consistent with a clinical-stage biotech: pre-revenue, dependent on milestone-driven capital raises, and targeting eventual FDA-approved therapeutic and diagnostic products for the celiac disease patient population. There is no disclosed pricing model, GTM motion, customer segmentation, partnership, or licensing revenue in the input data, and the company does not appear to have reached commercialization. As a result, revenue mechanics are entirely prospective, tied to future product launches rather than any current commercial activity.
ImmusanT firmographics
Firmographics- Name
- ImmusanT
- Website
- https://immusant.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ImmusanT is a Cambridge, Massachusetts-based clinical-stage biotechnology company founded in 2011 that develops diagnostics and therapeutics for celiac disease, funded by Vatera Healthcare Partners, ARCH Venture Partners, and the JDRF T1D Fund.
- Ownership category
- akta.pro rank
Where ImmusanT is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Markets served
ImmusanT business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
ImmusanT product offering
Product offeringCore offering
ImmusanT is a clinical-stage biotechnology company developing a peptide-based therapeutic vaccine (Nexvax2) and a blood-based companion diagnostic for the treatment and diagnosis of celiac disease. Its products are designed to induce immune tolerance to gluten in genetically susceptible patients and to provide a quantitative, blood-based alternative to current diagnostic methods. The company operates in the autoimmune disease therapeutics market with a focus on antigen-specific immunotherapy.
Product overview
No product information available from the source data. The website displayed only a security verification loading page.
Differentiator
Problem solved
Functional benefit
Products and services
- Nexvax2 A peptide-based therapeutic vaccine candidate targeting HLA-DQ2-restricted T-cell responses in celiac disease, designed to induce immune tolerance to gluten in genetically susceptible patients. Intended for adult celiac disease patients who continue to experience symptoms despite adherence to a gluten-free diet.
- Blood-based companion diagnostic for celiac disease A blood-based diagnostic test developed to detect and monitor celiac disease, intended to serve as a quantitative alternative to biopsy-based diagnosis and as a patient stratification and monitoring tool alongside ImmusanT's therapeutic vaccine.
Companies that use ImmusanT
Customer profileIdeal customer profiles2 records
ImmusanT technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
ImmusanT partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights3 records
ImmusanT competitors and assessment
Company assessmentBroad incumbents
- AbbVie: Major immunology-focused pharmaceutical company with deep autoimmune franchise (Humira/Skyrizi/Rinvoq). Acquired Alvine Pharmaceuticals (celiac-focused) and represents both a competitive threat and likely acquirer for celiac assets.
- Takeda Pharmaceutical: Global pharmaceutical company with a strong gastroenterology and rare disease franchise. Has pursued celiac disease assets and represents the strategic-acquirer / incumbent competitive landscape for celiac therapies.
Emerging players
- AnaptysBio: Clinical-stage immunology company developing therapeutics for autoimmune and inflammatory diseases. Comparable as a focused immunology/biotech peer operating in adjacent autoimmune indications.
- Topas Therapeutics: Developer of nanoparticle-based antigen-specific tolerance therapies for autoimmune indications. Comparable platform technology direction to ImmusanT's peptide-based tolerance approach.
Direct peers
- Provention Bio: Autoimmune therapeutics company developing disease-modifying therapies in immunology, including T1D and celiac-adjacent indications. Comparable in focus on autoimmune disease modification at clinical stage.
- Anokion: Clinical-stage immunology company developing antigen-specific tolerance therapies for autoimmune diseases, including celiac. Highly comparable to ImmusanT in modality (tolerogenic immunotherapy) and target disease.
- Kanyos Bio: Celiac-focused spin-out from Selecta Biosciences developing antigen-specific tolerance therapy for celiac disease. Closely comparable to ImmusanT in indication and modality.
- Selecta Biosciences: Pioneer in antigen-specific tolerance and tolerogenic immunotherapies; acquired Kanyos Bio (celiac-focused). Comparable to ImmusanT in tolerogenic vaccine approach for autoimmune disease.
- Cour Pharmaceuticals: Developer of antigen-specific immune tolerance therapies (Tregitope-based platform) with celiac disease as a lead indication. Directly comparable to ImmusanT in therapeutic modality and indication focus.
- Alvine Pharmaceuticals: Historical celiac-disease focused biopharmaceutical (acquired by AbbVie). Developed ALV003 (latiglutenase), a celiac digestive enzyme therapeutic — the most direct historical celiac competitor to ImmusanT's pipeline.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
ImmusanT social profiles
Digital presenceImmusanT financial estimates
Financial estimateRevenue estimate
Valuation estimate
ImmusanT leadership team
Management profileNumber of profiles
Profiles2 records
ImmusanT funding detail
Funding detailFunding overview
Funding rounds4 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ImmusanT M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ImmusanT
What does ImmusanT do?
ImmusanT is a clinical-stage biotechnology company developing a peptide-based therapeutic vaccine (Nexvax2) and a blood-based companion diagnostic for the treatment and diagnosis of celiac disease. Its products are designed to induce immune tolerance to gluten in genetically susceptible patients and to provide a quantitative, blood-based alternative to current diagnostic methods. The company operates in the autoimmune disease therapeutics market with a focus on antigen-specific immunotherapy.
Is ImmusanT a public or private company?
ImmusanT is a private company. It is classified as venture growth investor backed and is currently operating.
When was ImmusanT founded?
ImmusanT was founded in 2011. It employs 11 to 50 people.
Where is ImmusanT based?
ImmusanT is headquartered in Cambridge, United States, in the North America region.
Who are ImmusanT's main competitors?
Broad incumbents on record are AbbVie and Takeda Pharmaceutical. Emerging players are AnaptysBio and Topas Therapeutics. Direct peers are Provention Bio, Anokion, Kanyos Bio, Selecta Biosciences, Cour Pharmaceuticals and Alvine Pharmaceuticals.
Does ImmusanT have an API?
No public API is recorded for ImmusanT.